FA Community Call to Action!
FARA has prepared a letter to send to the Food and Drug Administration (FDA) and Reata Pharmaceuticals. This letter requests that Reata submit a New Drug Application (NDA) on an urgent basis and FDA to exercise the flexibility granted by law and contained in FDA guidance in considering approval of an NDA for Omaveloxolone in FA based on the existing evidence from clinical trials. The full letter is available at curefa.org/advocacy.

We are inviting the entire FA community (individuals with FA, family, friends, caregivers, supporters, other rare disease advocates) to sign-on in support. The sign-on period will remain open until January 20, 2021 at 5pm (Eastern). Signers will be identified in the letter by their affiliation with the FA community, first name, and last initial. Responses to question 5 may be quoted in the letter. The final letter with signature names will be sent to Reata, the FDA, and will posted on FARA's website upon completion.
Email address *
First Name *
Last Name *
1. Please indicate your country of residence. *
1a. If you reside in the United States, please select your state or territory.
2. Please indicate your affiliation with the FA Community. I am: *
3. If you or your child have FA, what is your / your child’s age?
4. Which of the following best describes your /your child’s stage of disease with FA?
Clear selection
5. If you or your immediate family member has or had FA, please respond to this question. Based on the data currently available on safety and efficacy of omaveloxolone would you, your child and/or your family member want the option of taking the drug/medicine? Please explain your response. If you participated in the MOXIe part 1, part 2 or open label extension study, please feel free to share your experience or observations.
A copy of your responses will be emailed to the address you provided.
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy